Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
December 05 2024 - 5:50AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of December 2024
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
EXHIBIT INDEX
|
Exhibit Number
|
Description
|
|
99.1
|
05
December 2024 - Board Changes
|
99.1
Haleon plc: Board Changes
5 December
2024: Haleon plc (the "Company" or "Haleon") (LSE/NYSE:
HLN) today announces the following changes to the
Board.
Following the reduction of Pfizer Inc.'s shareholding in
Haleon plc below 20%, and in line with the Pfizer Relationship
Agreement with Haleon plc, David Denton, Non-Executive Director
and
representative of Pfizer Inc., stepped down from the Board on 4
December 2024.
Bláthnaid Bergin has been appointed as an independent
Non-Executive Director and will join the Haleon Board on 24
February 2025.
Bláthnaid Bergin brings financial leadership and strategic
planning experience from a variety of consumer-facing businesses.
Bláthnaid is currently the Chief Financial Officer of J
Sainsbury plc, where she has played a pivotal role in driving the
company's financial strategy and operational efficiency
initiatives. Prior to joining Sainsbury's, Bláthnaid held
senior finance leadership and international positions at Aviva, RSA
and GE working across Europe, Asia and Australia. She is a
Chartered Accountant. Bláthnaid was previously Non-Executive
Director, Chair of the Audit Committee and Senior Independent
Director for Artemis Alpha Investment Trust.
Sir Dave Lewis, Haleon's Chair commented: "On behalf of the Board, I would like to
thank Dave for his insights and contributions to the Board's
discussions. We wish him all the very best for the future. I would
like to welcome Bláthnaid to Haleon. With her strong track
record of financial leadership and transformation from multiple
consumer-facing businesses, Bláthnaid brings a wealth of
relevant skills and experience to the Board."
The Company confirms that there is no further information to be
disclosed under the requirements of UKLR 6.4.6R and
6.4.8R.
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with
a purpose to deliver better everyday health with humanity. Haleon's
product portfolio spans five major categories - Oral Health, Pain
Relief, Respiratory Health, Digestive Health and Other, and
Vitamins, Minerals and Supplements (VMS). Its long-standing brands
- such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin,
Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
Date:
December 05, 2024
|
By:
|
/s/
Amanda Mellor
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|
Haleon (PK) (USOTC:HLNCF)
Historical Stock Chart
From Jan 2025 to Feb 2025
Haleon (PK) (USOTC:HLNCF)
Historical Stock Chart
From Feb 2024 to Feb 2025
